Shire is a specialty biopharmaceutical company with sales focusing on ADHD drugs and orphan drugs relating to genetic disorders (36% and 26% of revenues respectively). Because of this latter focus the company can earn high protected margins from the competition barriers in the orphan drug sector, which also partially shields the company from patent challenges thereby reducing their operational risk. The top 6 drugs account for 66% of the company’s revenues, making Shire susceptible to revenue volatility should generic competition exist for a product. Adderall (10% of revenues) is facing generic competition and should see it sales dwindle in the next few years, but Shire has a strong pipeline of new products which should make up for the loss in sales. Vyvanse, the largest revenue producer, is also in phase 3 trial for other disorders such as depression and schizophrenia. If successful would be a strong profit driver for Shire. The company is diversifying from the North American market (67% of sales) by trying to obtain 50% of their sales outside of North America and Europe by 2015.